173 related articles for article (PubMed ID: 36715297)
1. Comparing biologic options for the management of Behcet's disease-related uveitis.
Vitale A; Caggiano V; Berlengiero V; Perfetti MO; Sota J; Tosi GM; Frediani B; Cantarini L; Fabiani C
Expert Rev Clin Immunol; 2023 Mar; 19(3):315-328. PubMed ID: 36715297
[TBL] [Abstract][Full Text] [Related]
2. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
[TBL] [Abstract][Full Text] [Related]
3. Current and future treatments for Behçet's uveitis: road to remission.
Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A
Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309
[TBL] [Abstract][Full Text] [Related]
4. Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.
Sota J; Rigante D; Lopalco G; Frediani B; Franceschini R; Galeazzi M; Iannone F; Tosi GM; Fabiani C; Cantarini L
Rheumatol Int; 2018 Jan; 38(1):25-35. PubMed ID: 28752230
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.
Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M
Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542
[TBL] [Abstract][Full Text] [Related]
6. Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
Park Y; Cheon JH
Curr Gastroenterol Rep; 2020 Mar; 22(5):24. PubMed ID: 32193746
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
8. An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.
McNally TW; Damato EM; Murray PI; Denniston AK; Barry RJ
Orphanet J Rare Dis; 2017 Jul; 12(1):130. PubMed ID: 28716038
[TBL] [Abstract][Full Text] [Related]
9. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
Benitah NR; Sobrin L; Papaliodis GN
Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
[TBL] [Abstract][Full Text] [Related]
10. The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease.
Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Di Scala G; Sota J; Orlando I; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Ocul Immunol Inflamm; 2020; 28(2):298-304. PubMed ID: 30148652
[No Abstract] [Full Text] [Related]
11. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
Thomas AS
Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
[TBL] [Abstract][Full Text] [Related]
12. [Biologics in uveitis].
Feurer E; Bielefeld P; Saadoun D; Sève P
Rev Med Interne; 2015 Feb; 36(2):107-16. PubMed ID: 25239400
[TBL] [Abstract][Full Text] [Related]
13. Behçet's disease uveitis: is there a need for new emerging drugs?
Tugal-Tutkun I; Çakar Özdal P
Expert Opin Emerg Drugs; 2020 Dec; 25(4):531-547. PubMed ID: 33147420
[No Abstract] [Full Text] [Related]
14. Advances in pathogenesis and treatment of ocular involvement in Behcet's disease.
Lin S; Xu Z; Lin Z; Xie B; Feng J
Front Immunol; 2023; 14():1206959. PubMed ID: 37841268
[TBL] [Abstract][Full Text] [Related]
15. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review.
Bitossi A; Mattioli I; Bettiol A; Palermo A; Malandrino D; Bacherini D; Virgili G; Giansanti F; Vannozzi L; Silvestri E
Expert Rev Clin Immunol; 2023 May; 19(5):549-560. PubMed ID: 36939549
[TBL] [Abstract][Full Text] [Related]
16. Eye and Behçet's disease.
Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
J Fr Ophtalmol; 2019 Apr; 42(4):e133-e146. PubMed ID: 30850197
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients.
Barroso-García N; Atienza-Mateo B; Ferraz-Amaro I; Prieto-Peña D; Beltrán E; Adán A; Hernández-Garfella M; Martínez-Costa L; Cordero-Coma M; Díaz-Llopis M; Herreras JM; Maíz-Alonso O; Torre-Salaberri I; De Vicente-Delmás A; Díaz-Valle D; Atanes-Sandoval A; Francisco F; Insua S; Sánchez J; Almodóvar-González R; Jiménez-Sosa A; Ruiz-Moreno O; Gandía-Martínez M; Nolla JM; Calvo-Río V; Castañeda S; González-Gay MA; Blanco R
Semin Arthritis Rheum; 2023 Feb; 58():152153. PubMed ID: 36549244
[TBL] [Abstract][Full Text] [Related]
18. [Uveitic glaucoma in Behçet's disease: When everything gets complicated].
Belkhadir K; Boutimzine N; Tachfouti S; Laghmari M; Amazouzi A; Cherkaoui O
J Fr Ophtalmol; 2020 Sep; 43(7):635-641. PubMed ID: 32622636
[TBL] [Abstract][Full Text] [Related]
19. Biologic therapy for Behçet's uveitis: a systematic review.
Uke P; Gorodkin R; Beare N
Br J Ophthalmol; 2020 Aug; 104(8):1045-1051. PubMed ID: 31676596
[TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
